Drugs that contain Troglitazone
1. Prelay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5602133 | SANKYO | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
Sep, 2013
(10 years ago) | |
| US6046202 | SANKYO | Use of thiazolidinedione derivatives in the treatment of insulin resistance |
Sep, 2013
(10 years ago) | |
| US6011049 | SANKYO | Combinations for diabetes |
Nov, 2017
(6 years ago) | |
| US5859037 | SANKYO | Sulfonylurea-glitazone combinations for diabetes |
Nov, 2017
(6 years ago) | |
Market Authorisation Date: 29 January, 1997
Treatment: Administration to a host suffering from gestational diabetes; Method of using troglitazone to treat patients having insulin resistance; Use of troglitazone in combination with sulfonylureas and biguan...
Dosage: TABLET;ORAL
More Information on Dosage
PRELAY family patents
2. Rezulin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5602133 | PFIZER PHARMS | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
Sep, 2013
(10 years ago) | |
| US6046202 | PFIZER PHARMS | Use of thiazolidinedione derivatives in the treatment of insulin resistance |
Sep, 2013
(10 years ago) | |
| US5859037 | PFIZER PHARMS | Sulfonylurea-glitazone combinations for diabetes |
Nov, 2017
(6 years ago) | |
| US6011049 | PFIZER PHARMS | Combinations for diabetes |
Nov, 2017
(6 years ago) | |
Market Authorisation Date: 29 January, 1997
Treatment: Administration to a host suffering from gestational diabetes; Method of using troglitazone to treat patients having insulin resistance; Use of troglitazone in combination with sulfonylureas in the tre...
Dosage: TABLET;ORAL
More Information on Dosage
REZULIN family patents